Perceptive Capital Solutions Corp · NASDAQ:PCSC
Perceptive Capital Solutions — SPAC Merger (May 2026)
87 slides from Perceptive Capital Solutions's SPAC merger presentation, May 19, 2026
Slide 1: Harnessing the Power of a Multiomics, AI/ML-Based Platform Learning Engine
Harnessing the Power of a Multiomics, AI/ML-Based Platform Learning Engine Setting a New Pace for Early Cancer Detection May 2026 Analyst Day
Slide 2: Disclaimer
Disclaimer This presentation (together with oral statements made in connection herewith, this “Presentation”) is provided for informational purposes only. This Presentation has been prepared to assist interested parties in making their own evaluation with respect to an investment in connection with
Slide 3: Disclaimer (Cont'd)
Disclaimer (Cont’d) Participants in the Solicitation In connection with the Proposed Business Combination, PCSC and Freenome have prepared and filed with the SEC a registration statement containing a preliminary proxy statement of PCSC and a preliminary prospectus with respect to securities to be of
Slide 4: Disclaimer (Cont'd)
Disclaimer (Cont’d) Neither PCSC nor Freenome presently know or that PCSC and Freenome currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect PCSC’s and Freenome’s expecta
Slide 5: Session 1: Overview and objectives for the day
Session 1: Overview and objectives for the day Aaron Elliott (CEO) Riley Ennis (Co-Founder, CPO)
Slide 6: Analyst Day Agenda
Analyst Day Agenda May 19, 2026 | 8:00 AM to 2:00 PM 8:00-8:15 Welcome & Breakfast 8:15-8:30 Session 1: Overview and objectives for the day Aaron + Riley 8:30-8:50 Session 2: Investment thesis & highlights Aaron 8:50-9:20 Session 3: Product & platform architecture Riley + Jimmy 9:20-9:50 Session 4:
Slide 7: Source: HealthTech Company Overview - Freenome (YouTube)
Source: HealthTech Company Overview - Freenome (YouTube)
Slide 8: Today's key leadership team presenters and participants
Today’s key leadership team presenters and participants Sally Howard, JD SVP, Regulatory & Quality Bradley Carr VP, Lab Operations Aaron Elliott, PhD Chief Executive Officer Riley Ennis Co-Founder, Chief Product Officer Linh H. Le Chief Financial Officer Julie Tran Chief People Officer Jimmy Lin MD,
Slide 9: Key Investment Highlights
Key Investment Highlights Aim to transform early cancer detection with a suite of blood-based tests that target a $50B market opportunity 1 Our tests are built on a novel multiomics, AI/ML-based platform, which is designed to deliver sustainable performance advantages, data moat, and rapid test vers
Slide 10: Freenome at a glance
Freenome at a glance Our mission is to save lives through early cancer detection using a simple blood test Founded 2014 TotalEmployees ~390 R&DScientists ~205 Clinical and R&D Lab Space ~120k sq ft Automated Lab Process ~80% Freenome Work Cell Campus and lab infrastructure built for scale
Slide 11: ~$1.3 Billion raised from a diverse, deep investor base
~$1.3 Billion raised from a diverse, deep investor base including strategics Technology Biotech Health care Biopharma &other strategics Mutual &public funds *Subset of current investors.
Slide 12: Multiple value-driving catalysts on the horizon in CRC, lung, and PCD
Multiple value-driving catalysts on the horizon in CRC, lung, and personalized cancer detection (PCD)* Early Access Program (EAP); Analytical/Clinical Validation (AV/CV): United States Preventive Services Task Force (USPSTF); Laboratory Developed Test (LDT); In Vitro Diagnostic (IVD) Anticipated Mil
Slide 13: Session 2: Investment Thesis & Highlights
Session 2: Investment Thesis & Highlights Aaron Elliott (CEO)
Slide 14: Today's cancer screening paradigm is flawed
~90% 5-year survival rate for certain common cancers when caught early**4 ~50% of cancers detected at advanced stage 3 Only ~14% of diagnosed cancers are detected by screening 2 Today’s cancer screening paradigm is flawed; a new approach is necessary to empower everyone to access recommended cancer
Slide 15: Multiomics signals + AI/ML enable early cancer detection
Multiomics signals + AI/ML enable early cancer detection Integrate signals across modalities and improve over time. Commercial testing generates real-world data for continuous improvement Real-World Data (RWD) Feedback Loop Diverse set of signals for early detection across a range of cancers Combina
Slide 16: CRC screening provides the largest, reimbursed entry point
CRC screening provides the largest, reimbursed entry point for our personalized multi-cancer detection pipeline *Breakdown is based on management estimates. Starting with the Largest Screening Population ~120M people in the U.S. are eligible for CRC screening, yet ~40-50M remain unscreened; CRC rema
Slide 17: Population-level CRC screening as foundation for multi-cancer detection
Single Cancer CRC / AA Lung Liver Etc. Multi-Cancer Smoking Obesity GERD Genetic / Other Risk Factors Single-cancer early detection tests based on reimbursement pathway starting with CRC … … Is expected to enable future multi-cancer early detection tests leveraging a common platform based on reimbur
Slide 18: Freenome combining with Perceptive Capital Solutions
A leading New York-based investment firm with 26 years of experience investing in the healthcare sector ~$7.5B of assets under management Successful track record of leadership in biotech investing and innovative company formation Has successfully executed and closed four high-profile life sciences d
Slide 19: Session 3: Product & Platform Architecture
Session 3: Product & Platform Architecture Riley Ennis (Co-Founder, CPO) Jimmy Lin (CSO)
Slide 20: Freenome's PCD Approach
Freenome’s PCD Approach Single Cancer Detection (SCD) Multi Cancer Detection (MCD) 50 Cancers Sensitivity Specificity Multiple Tests Freenome’s solution Specificity Specificity Sensitivity Sensitivity
Slide 21: Parallelized multiomics discovery and high-throughput production platforms
Freenome’s parallelized multiomics discovery and high-throughput production platforms to drive blood test development and scalable data generation CommercialTesting High-Throughput, Targeted Assays for Commercial Applications Discovery (R&D)Multiomics Platform Broad Discovery Assays Embedded Multi-C
Slide 22: Differentiated Single-Omic Assay: Non-bisulfite, base-level epigenetic assay
Differentiated Single-Omic Assay: Non-bisulfite, base-level epigenetic assay Our NGS workflow for methylation and other epigenetic biomarkers uniquely provides multimodal digital outputs at base-level enabling us to capture subtle biological changes important for early-stage lesions and core to any
Slide 23: Multiomics for low and high shedding tumors
Multiomics for low and high shedding tumors may be required to reach clinically-meaningful performance levels Hsu TK et al., Cancer Res. (2021) Sensitivity (n = 230) ctDNA shedding rate Low High Sensitivity (n = 39) DNA + Protein only
Slide 24: Disease detection AI/ML model evolution
Disease detection AI/ML model evolution in anticipation of future commercial data volume Machine learning Deep learning Current and Future Product Models Future Potential Models • Explicit feature engineering informed by biology, assay behavior, and curated priors. • Model learns representations dir
Slide 25: Session 4: CRC & Lung Anchors
Session 4: CRC & Lung Anchors Sally Howard (SVP of Quality & Regulatory) Jimmy Lin (CSO) Riley Ennis (Co-Founder, CPO)
Slide 26: Freenome Test Pipeline
Freenome Test Pipeline: Anchored by our blood-based CRC v1 screening test meeting the requirements for FDA approval and Medicare coverage SimpleScreen CRC v1 FDA approval & Medicare reimbursement (expected 2H ‘26) Clinically- Validated in PREEMPT CRC, the largest study of its kind (n>40k participant
Slide 27: FDA PMA Approval timeline
FDA PMA Approval PMA Modules 1 & 2 (M1 & M2) 2026 2025 Prior PMA Modules 1 & 2 reviewed by FDA 2H ‘24 Module 3 Submission: Submitted 1H ‘25 Module 4 Submission: Submitted Mid ‘25 PAI and BIMO Audit Readiness: 2H ‘25 1H 2H Successful PAI Inspection Q1 ‘26 Anticipated IVD Launch Readiness: 1H ‘26 Anti
Slide 28: Test Versioning Programs
Test Versioning Programs Final v2 Design DNA Extraction ✓ NGS Conversion ✓ NGS Platform (Library Prep, Multiplex, Capture, Sequencing) ✓ Process/reagent variability reduction (Mitigate degradation) ✓ Computational ✓ Assay Analytical Performance ~3x cfDNA molecule recovery compared to v1 Analytical P
Slide 29: SimpleScreen CRC Potentially Best-in-Class Performance Among Blood-Based Tests
Sensitivity*** Specificity Company Test FDA Status Advanced Adenoma High-Grade Dysplasia Stage ICRC OverallCRC Overall SimpleScreen CRC v1 PMA**Submittedin Aug’25 14% 31% 64% 81% 90% SimpleScreen CRC v2* sPMA** SubmissionAnticipated in 2H26 22% 44% 75% 85% 90% Shield v1 FDA Approved in Jul’24 13% 23
Slide 30: Improved detection rates for CRC and APLs
Improved detection rates were observed for CRC and APLs, including Stage I CRC 0 25 50 75 100 Adjusted sensitivity CRC adjusted sensitivity by stage A. B. Updated test Previous test Overall I (T1) II III IV 83.5 85.2 68.3 69.9 80.5 86.0 82.5 82.5 97.1 98.4 100.0 100.0 I (T2) Stage 0 25 50 75 100 Adj
Slide 31: Updated test showed improvements in lifetime CRC cases, deaths, and life years gained
Updated test showed meaningful improvements in lifetime CRC cases, deaths, and life years gained (LYG) 1. Meester RGS et al. JNCI J Natl Cancer Inst. 2025:djaf277 No screening Previous test Updated test Number per 1000 adults 0 25 50 75 86.4 42.9 39 CRC cases 0 10 20 30 33.3 13.9 12.5 CRC deaths LYG
Slide 32: Microsimulation model (COSMOS-CRC1)
We deployed a microsimulation model (COSMOS-CRC1) similar to the models used to inform USPSTF recommendations Assumptions: the cohort screened from age 45 to 75 with a triennial blood-based test; individuals with positive results received follow-up colonoscopy; individuals with detected adenomas rec
Slide 33: Lung: Significant unmet need for eligible individuals
Lung: Significant unmet need for ~14-15M individuals annually in the U.S. Eligible for Lung Cancer Screening per Guidelines 1 Freenome’s Lung Target Product Profile: Frontline Screening Triaged by Low-Dose CT (LDCT) Early Detection Makes an Impact Lung & Bronchus Survival Rates, Local vs. Metastatic
Slide 34: Multiple cancer screening tests from a single blood draw
The ability to offer multiple cancer screening tests for eligible populations from a single blood draw could have even greater benefit in increasing adherence Potter, A et al., (2025). Preventive Health Care Use Among Adults Eligible for Lung Cancer Screening in the US. JAMA, 333(18), 1635-1638. Dua
Slide 35: SimpleScreen Lung Program: Feasibility Evaluation Cohort
Age: 50-80 years 20+ pack-years SimpleScreenTM Lung Program: Feasibility Evaluation Cohort Age: 50-80 years 20+ pack-years Stage I (N = 98) Stage II (N = 63) Stage Ill (N = 103) Stage IV (N = 99) Study Source: Subset of Vallania (NCT05254834) Design: Case-control Method: AI/ML-driven multiomics plat
Slide 36: Assessing Performance Across Lung Cancer Stages & Histological Subtypes
Assessing Performance Across Lung Cancer Stages & Histological Subtypes Stage I Stage II Stage III Stage IV Total Adenocarcinoma * 67 31 48 62 208 Squamous Cell Carcinoma* 28 23 45 24 120 Small Cell Lung Cancer** 2 9 10 13 34 Unknown Histology 1 0 0 0 1 Total 98 63 103 99 363 Evaluation Cohort (Plas
Slide 37: Multiomics Increases Lung Cancer Detection
Multiomics Increases Lung Cancer Detection via Additive cfDNA Methylation and Plasma Protein Signals Specificity Model 50% 75% Multiomic* (cfDNA Methylation + Plasma Proteins) 90.7% 80.4% cfDNA Methylation only 85.8% 78.2% Plasma Proteins only 83.8% 68.7% IUP-Adjusted Sensitivities Combining base-re
Slide 38: Robust IUP-Adjusted Sensitivities Across Lung Cancer Stages and Subtypes
Robust IUP-Adjusted Sensitivities Maintained Across All Lung Cancer Stages and Three Major Histological Subtypes 95% confidence intervals (CIs) were computed via Wilson’s method.
Slide 39: SimpleScreen Lung Program: Feasibility Milestone Achieved
SimpleScreenTM Lung Program: Feasibility Milestone Achieved Abstract presented at AACR 2026. 1PROACT-LUNG: Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening (NCT06122077). Laboratory Developed Test (LDT); Premarket Approval (PMA). Lung Feasibility Complete SimpleScreen
Slide 40: Session 5: Product / Reimbursement Deep Dive
Session 5: Product / Reimbursement Deep Dive Riley Ennis (Co-Founder, CPO) Rob Guigley (CCO)
Slide 41: Personalized Cancer Detection with CRC and Lung as Anchor Indications
Patient Profile 50 years old Male GERD Cirrhosis Former smoker with a ≥20 pack-year smoking history PCD to Identify the Right Cancer Test(s) for the Right Patient with CRC and Lung as Freenome’s Anchor Indications Freenome’s Personalized Menu CRC (Anticipated FDA approval mid-2026) Lung (LDT launch
Slide 42: Overlapping Patient Eligibility Drives Personalized Multi-Cancer Testing
Overlapping Patient Eligibility Drives Personalized Multi-Cancer Testing Total CRC Screening Population 45+ (~120M+) CRC Eligible Only ~15M Dual Eligible (CRC & Lung) CRC + Lung (Smokers) ~30M Dual Eligible (CRC & Esophageal) CRC + Esophageal (GERD) Full CRC reimbursement to Freenome when ordered al
Slide 43: Indication TAM additivity
DeciBio Synthesis and Analysis; Monte Carlo Simulation, April 2026 Indication TAM additivity is illustrative and adjusts based on deployment order Indication TAM may be adjusted based on intended use population changes 84% of the ~120M patients recommended for CRC screening are potentially eligible
Slide 44: Session 6: Commercial Model & Health-System Strategy
Session 6: Commercial Model & Health-System Strategy Aaron Elliott (CEO) Rob Guigley (CCO)
Slide 45: Freenome's Commercial Ecosystem
Freenome’s Commercial Ecosystem Supports Efficient but Expansive Footprint Exact Sciences’ commercial engine is designed to drive CRC test adoption through primary care channel and allow Freenome to focus on multi-cancer eligible patients (e.g. CRC + lung or CRC + esophageal, etc.) through health sy
Slide 46: Partnership with Exact Sciences
Partnership with Exact Sciences not only validates our CRC data and product-market fit but also provides significant near- and long-term benefits In August 2025, Freenome announced an exclusive U.S. license agreement with Exact Sciences to commercialize Freenome’s blood-based CRC test if approved in
Slide 47: Breakdown of potential $700M regulatory and market access milestone payments
Breakdown of potential $700M regulatory and market access milestone payments $100M CRC v1 first-line FDA approval $100M CRC v2 first-line sPMA approval and tech transfer to Abbott Cancer Diagnostics (formerly Exact Sciences) Alternative v2 milestone: $50M minimum; up to $100M total based on v2 perfo
Slide 48: Exclusive license and option with Roche
Freenome and Roche have entered into an exclusive license and option for up to $209M to develop and commercialize an ex-US kitted version of Freenome’s Personalized MCED test on Roche’s SBX sequencing platform The deal strengthens Roche’s initial investments in Freenome (~$400M before this transacti
Slide 49: Differentiated health systems strategy
Differentiated health systems strategy expected to drive testing and achieve low cost per sale through direct integrations Centralized decision making while covering a large percentage of PCPs has the potential to scale test adoption while maximizing commercial resources Multi-cancer early detection
Slide 50: Freenome Digital Health
Freenome Digital Health: To maximize the success of this salesforce we will deploy a reinforcing lever expected to drive adoption and stickiness Freenome Digital Health Play To target health systems, testing companies require a “hook”-a reason that health system leaders should be interested in worki
Slide 51: Session 7: Integrated AI/ML Roadmap
Session 7: Integrated AI/ML Roadmap Riley Ennis (Co-Founder, CPO) Jimmy Lin (CSO)
Slide 52: AI infrastructure under development ahead of commercial launch
AI infrastructure under development ahead of commercial launch to activate learning engine with health systems for generating paired molecular and clinical datasets Freenome provides: CRC blood-based testing (if approved) AI-enabled learning engine Real-world data (RWD) and informatics Future blood
Slide 53: Intersection of high-volume, longitudinal, and deep molecular data generation
Freenome is at the intersection of high-volume, longitudinal, and deep molecular data generation with commercial launch underway Ks of tests / ~5-500 biomarkers While volumes for commercially available cancer tests today are high, the number of biomarkers tested, and thus utility of the data, is lim
Slide 54: Multiple instance learning (MIL)
Multiple instance learning (MIL) applies a single classification label to a collection (“bag”) of objects (“instances”) Most instances in the bag are not informative for its label, but a few, key “witness instances” are The MIL challenge: the learner is never provided with instance-level labels duri
Slide 55: Extreme-scale MIL: Millions of fragments and ultra-sparse signal
Extreme-scale MIL: Millions of fragments and ultra-sparse signal One bag of cfDNA fragments per patient, and each fragment is an instance Each fragment/instance is a unit of reasoning and can be considered as a token Fragments are embedded into multimodal vectors 1M to 10M instances/tokens per patie
Slide 56: Proprietary Fragment-Level Deep Learning (FLDL) model
Proprietary Fragment-Level Deep Learning (FLDL) model optimizes learning efficiency in preparation for large commercial data volume for future test versions Fragment data M fragments with base-level features Fragment Embedding Processing and combination of pairwise features into a single fixed-sized
Slide 57: FLDL outperforms ML Baseline in an independent clinical cohort
FLDL outperforms ML Baseline in an independent clinical cohort 1 Model APL sensitivity CRC sensitivity ML Baseline 27.1% 88.2% PD-FLDL 30.2% 89.6% C-FLDL 28.9% 89.1% ER-FLDL 28.4% 88.2% PD-MaxPool 19.9% 79.2% C-MaxPool 17.3% 76.3% Holdout Clinical Test Cohort 331 negatives and 599 positives, includi
Slide 58: FLDL's sample embedding: Interpretability and few-shot transfer
FLDL’s sample embedding: Interpretability and few-shot transfer to new cancer types High ctDNA No/low ctDNA Two-dimensional UMAP of sample-level embeddings shows that ctDNA content is a major axis of separation Healthy samples co-locate, as do cancer samples — both lung cancer cases and advanced col
Slide 59: cfDNA data alone creates deep learning scaling challenges
cfDNA data alone creates deep learning scaling challenges Current training < 10K samples 1-10 M tokens per sample 1 2 3 Critical need for NVIDIA next-generation GPUs as training data volume and inference scale grows Future training 100K - 1M samples 10M+ tokens per sample Commercial scale inference
Slide 60: Long-Term Vision: Longitudinal Patient Embeddings
Long-Term Vision: Longitudinal Patient Embeddings Repeated blood sampling creates longitudinal molecular signals to potentially enhance accuracy Trajectory modeling predicts disease emergence and progression Multimodal signals refine patient state representations Freenome Multimodal Foundation Model
Slide 61: Session 8: Roadmap & Future Milestones
Session 8: Roadmap & Future Milestones Aaron Elliott (CEO) Riley Ennis (Co-Founder, CPO)
Slide 62: Multiple value-driving catalysts on the horizon in CRC, lung, and PCD
Multiple value-driving catalysts on the horizon in CRC, lung, and PCD* Early Access Program (EAP); Analytical/Clinical Validation (AV/CV): United States Preventive Services Task Force (USPSTF); Laboratory Developed Test (LDT); In Vitro Diagnostic (IVD) Anticipated Milestones** 2025 2026 2027 H2 H1 H
Slide 63: Personalized Cancer Detection: Product Timeline
PCD Readout CRC V1 approval Lung LDT launch Q4 Q3 Q4 Q1 Q3 Q4 Q1 Q2 CRC/AA v2 & Lung v1 LDT Readouts Personalized Cancer Detection: Product Timeline 2H25 1H26 2H26 1H27 2H27 Based on management estimates. Projections are subject to inherent limitations, and timelines for regulatory approvals may var
Slide 64: Personalized Cancer Detection: Discovery Roadmap
Discovery* Tissue and Plasma Biobanks from Vallania, Sanderson, and other collections Cancer Signal Origin (CSO) Algorithm Refinement (Backbone to enable Average-Risk MCED) Personalized Cancer Detection: Discovery Roadmap *All of the indications are in the discovery phase and there is no set time fr
Slide 65: Session 9: Operations & Lab
Session 9: Operations & Lab Jimmy Lin (CSO) Riley Ennis (Co-Founder, CPO) Bradley Carr (VP of Lab Operations)
Slide 66: Lab & Facilities Tour Primer
Lab & Facilities Tour Primer Clinical and R&D Lab Space ~120k sq ft Automated Lab Process ~80% Freenome Work Cell
Slide 67: Lab & Facilities Tour
Freenome Lab & Facilities Tour
Slide 68: Session 10: Public-Company Setup & Transaction Overview
Session 10: Public-Company Setup & Transaction Overview Linh Le (CFO) Riley Ennis (Co-Founder, CPO)
Slide 69: Transaction Summary and Rationale
Transaction Summary and Rationale Transaction Summary Freenome Holdings, Inc. (“Freenome”) and Perceptive Capital Solutions Corp (“PCSC”, Nasdaq:PCSC) to merge pursuant to a business combination agreement to be entered into between PCSC and Freenome Freenome is a healthcare company utilizing its und
Slide 70: Terms of Transaction
Terms of Transaction(2) Pro Forma Valuation Pro Forma Ownership Sources of Funds Uses of Funds Shares and $ in thousands (other than share price) Pipe Price At Closing Implied Share Price $10.00(1) $10.65(1) Pro Forma Shares Outstanding 112,577 112,577 PF Equity Value $1,125,770 $1,198,945 Less: PF
Slide 71: Moderated Q&A
Freenome Moderated Q&A
Slide 72: Session 11: Closing Remarks & Key Takeaways
Session 11: Closing Remarks & Key Takeaways Aaron Elliott (CEO) Riley Ennis (Co-Founder, CPO)
Slide 73: Risk Factors (1 of 14)
Risk Factors (1 of 14) Certain factors may have a material adverse effect on our business, financial condition and results of operations. The risks and uncertainties described below are not the only ones we and the post-business combination public company will face. Additional risks and uncertaintie
Slide 74: Risk Factors (2 of 14)
Risk Factors (2 of 14) Risks Related to Our Business and Financial Condition (continued) Our approach to the development of multiple blood-based screening tests through the use of our technology platform is unproven, which makes it difficult to predict the time, cost of development and likelihood of
Slide 75: Risk Factors (3 of 14)
Risk Factors (3 of 14) Risks related to Product Development and Commercialization Failure of, or defects in, our machine learning algorithms, artificial intelligence, and cloud-based computing infrastructure, including interruptions of service through third-party service providers, or increased regu
Slide 76: Risk Factors (4 of 14)
Risk Factors (4 of 14) Risks related to Government Regulation (continued) If the third parties on which we rely for the conduct of our clinical trials and results do not perform our clinical trial activities in accordance with good clinical practices and related regulatory requirements, we may be un
Slide 77: Risk Factors (5 of 14)
Risk Factors (5 of 14) Risks related to Government Regulation (continued) If third-party payers, including commercial payers and government healthcare programs, do not provide coverage of, or adequate reimbursement for, our tests, our business and results of operations will be negatively affected. T
Slide 78: Risk Factors (6 of 14)
Risk Factors (6 of 14) Risks related to Intellectual Property If we are unable to obtain and maintain intellectual property protection for our technology, or if the scope of the intellectual property protection we obtain is not sufficiently broad, our competitors may develop and commercialize techno
Slide 79: Risk Factors (7 of 14)
Risk Factors (7 of 14) Risks related to Intellectual Property (continued) Future issued patents covering our products and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the U.S. and abroad. We may be subject to claims asserting th
Slide 80: Risk Factors (8 of 14)
Risk Factors (8 of 14) General risk factors If we fail to establish and maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and othe
Slide 81: Risk Factors (9 of 14)
Risk Factors (9 of 14) Risks Related to the Business Combination and PCSC (continued) The Business Combination may be completed even though material adverse effects may result from the public announcement or completion of the proposed Business Combination, general business or economic conditions, in
Slide 82: Risk Factors (10 of 14)
Risk Factors (10 of 14) Risks Related to the Business Combination and PCSC (continued) If the conditions to the Business Combination Agreement are not met, the Business Combination may not occur. During the pendency of the Business Combination, Freenome and PCSC are prohibited from entering into cer
Slide 83: Risk Factors (11 of 14)
Risk Factors (11 of 14) Risks Related to the Business Combination and PCSC (continued) If, before distributing the proceeds in the trust account to our public shareholders, we file a bankruptcy or winding up petition or an involuntary bankruptcy or winding up petition is filed against us that is not
Slide 84: Risk Factors (12 of 14)
Risk Factors (12 of 14) Risks Related to the Business Combination and PCSC (continued) We are an emerging growth company and a smaller reporting company within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements available to “emerging growth
Slide 85: Risk Factors (13 of 14)
Risk Factors (13 of 14) Risks Related to the Redemption Public Shareholders who wish to redeem their public shares for a pro rata portion of the trust account must comply with specific requirements for redemption that may make it more difficult for them to exercise their redemption rights prior to t
Slide 86: Risk Factors (14 of 14)
Risk Factors (14 of 14) Risks if the Domestication and the Business Combination are not Consummated If we are not able to complete the Business Combination with Freenome nor able to complete another business combination by June 13, 2026, in each case, as such date may be extended pursuant to our Exi
Slide 87: Additional Information about the Proposed Business Combination and Where to Find It
Additional Information about the Proposed Business Combination and Where to Find It The proposed Business Combination will be submitted to shareholders of PCSC for their consideration. PCSC intends to file a registration statement on Form S-4 with the SEC, which will include preliminary and definiti
Perceptive Capital Solutions — SPAC Merger (May 2026) on 6ix